Np mrd loader

Record Information
Version2.0
Created at2022-04-27 22:20:02 UTC
Updated at2022-04-27 22:20:02 UTC
NP-MRD IDNP0050879
Secondary Accession NumbersNone
Natural Product Identification
Common NameIbogaine
DescriptionIbogaine, also known as endabuse, belongs to the class of organic compounds known as ibogan-type alkaloids. These are indole alkaloids with a structure based on the ibogamine skeleton or a derivative thereof. Ibogamine is a pentacyclic heterocyclic compound consisting of an indole fused to an azepane-containing tricyclic moiety ring. Iboga alkaloids arise from the cyclization of a secodine-type precursor through the formation of a 16,21 bond. Ibogaine is a secondary metabolite. Secondary metabolites are metabolically or physiologically non-essential metabolites that may serve a role as defense or signalling molecules. In some cases they are simply molecules that arise from the incomplete metabolism of other secondary metabolites. Ibogaine is found in Tabernaemontana divaricata, Ervatamia officinalis , Tabernaemontana bovina, Tabernaemontana crassa, Tabernanthe iboga , Trachelospermum jasminoides and Voacanga thouarsii. Ibogaine was first documented in 2007 (PMID: 17698848). Based on a literature review a small amount of articles have been published on ibogaine (PMID: 30471678) (PMID: 18650249) (PMID: 30216039) (PMID: 30471681).
Structure
Thumb
Synonyms
ValueSource
(-)-IbogaineChEBI
12-MethoxyibogamineChEBI
EndabuseChEBI
12 MethoxyibogamineMeSH
Chemical FormulaC20H26N2O
Average Mass310.4410 Da
Monoisotopic Mass310.20451 Da
IUPAC Name(1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.0^{2,10}.0^{4,9}.0^{13,18}]nonadeca-2(10),4,6,8-tetraene
Traditional Name(1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.0^{2,10}.0^{4,9}.0^{13,18}]nonadeca-2(10),4,6,8-tetraene
CAS Registry NumberNot Available
SMILES
CC[C@H]1C[C@@H]2C[C@@H]3[C@H]1N(C2)CCC1=C3NC2=CC=C(OC)C=C12
InChI Identifier
InChI=1S/C20H26N2O/c1-3-13-8-12-9-17-19-15(6-7-22(11-12)20(13)17)16-10-14(23-2)4-5-18(16)21-19/h4-5,10,12-13,17,20-21H,3,6-9,11H2,1-2H3/t12-,13+,17+,20+/m1/s1
InChI KeyHSIBGVUMFOSJPD-CFDPKNGZSA-N
Experimental Spectra
Not Available
Predicted Spectra
Spectrum TypeDescriptionDepositor IDDepositor OrganizationDepositorDeposition DateView
1D NMR13C NMR Spectrum (1D, 25 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 100 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 252 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 1000 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 50 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 200 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 75 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 300 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 101 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 400 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 126 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 500 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 151 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 600 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 176 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 700 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 201 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 800 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 226 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 900 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
Chemical Shift Submissions
Not Available
Species
Species of Origin
Species NameSourceReference
Ervatamia coronariaLOTUS Database
Ervatamia officinalisPlant
Tabernaemontana bovinaPlant
Tabernaemontana crassaPlant
Tabernanthe ibogaPlant
Trachelospermum jasminoidesPlant
Voacanga thouarsiiPlant
Chemical Taxonomy
Description Belongs to the class of organic compounds known as ibogan-type alkaloids. These are indole alkaloids with a structure based on the ibogamine skeleton or a derivative thereof. Ibogamine is a pentacyclic heterocyclic compound consisting of an indole fused to an azepane-containing tricyclic moiety ring. Iboga alkaloids arise from the cyclization of a secodine-type precursor through the formation of a 16,21 bond.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassIbogan-type alkaloids
Sub ClassNot Available
Direct ParentIbogan-type alkaloids
Alternative Parents
Substituents
  • Ibogan skeleton
  • Catharanthine skeleton
  • 3-alkylindole
  • Pyrroloazepine
  • Indole
  • Indole or derivatives
  • Anisole
  • Alkyl aryl ether
  • Azepine
  • Aralkylamine
  • Benzenoid
  • Piperidine
  • Heteroaromatic compound
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Organoheterocyclic compound
  • Azacycle
  • Ether
  • Organooxygen compound
  • Organonitrogen compound
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Organopnictogen compound
  • Organic oxygen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Physical Properties
StateNot Available
Experimental Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Predicted Properties
PropertyValueSource
logP4.23ALOGPS
logP3.53ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)17.08ChemAxon
pKa (Strongest Basic)8.97ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area28.26 ŲChemAxon
Rotatable Bond Count2ChemAxon
Refractivity93.57 m³·mol⁻¹ChemAxon
Polarizability36.68 ųChemAxon
Number of Rings5ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
HMDB IDNot Available
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FoodDB IDNot Available
KNApSAcK IDC00001741
Chemspider ID170667
KEGG Compound IDNot Available
BioCyc IDCPD-21566
BiGG IDNot Available
Wikipedia LinkIbogaine
METLIN IDNot Available
PubChem Compound197060
PDB IDNot Available
ChEBI ID5852
Good Scents IDNot Available
References
General References
  1. Barsuglia JP, Polanco M, Palmer R, Malcolm BJ, Kelmendi B, Calvey T: A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. Prog Brain Res. 2018;242:121-158. doi: 10.1016/bs.pbr.2018.08.002. Epub 2018 Oct 25. [PubMed:30471678 ]
  2. Jacobs MT, Zhang YW, Campbell SD, Rudnick G: Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter. J Biol Chem. 2007 Oct 5;282(40):29441-7. doi: 10.1074/jbc.M704456200. Epub 2007 Aug 13. [PubMed:17698848 ]
  3. Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V: Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Hum Exp Toxicol. 2008 Mar;27(3):181-94. doi: 10.1177/0960327107087802. [PubMed:18650249 ]
  4. Wasko MJ, Witt-Enderby PA, Surratt CK: DARK Classics in Chemical Neuroscience: Ibogaine. ACS Chem Neurosci. 2018 Oct 17;9(10):2475-2483. doi: 10.1021/acschemneuro.8b00294. Epub 2018 Oct 9. [PubMed:30216039 ]
  5. Corkery JM: Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers. Prog Brain Res. 2018;242:217-257. doi: 10.1016/bs.pbr.2018.08.005. Epub 2018 Oct 12. [PubMed:30471681 ]